Pathogen intracellular proteins and enzymes

Pathogen intracellular proteins and enzymes represent a broad and diverse category of therapeutic targets essential for the survival, replication, and pathogenesis of bacteria, viruses, fungi, and protozoa. These targets include critical enzymes such as DNA gyrase, RNA polymerase, and various proteases, as well as structural components like ribosomal subunits (NCBI, 2021). In bacterial infections, drugs like fluoroquinolones inhibit DNA topoisomerases to prevent genome replication, while macrolides bind to the 50S ribosomal subunit to halt protein synthesis (StatPearls, 2023). Viral intracellular targets often include reverse transcriptase, integrase, and proteases, which are pivotal for the life cycle of viruses such as HIV and HCV (NIH, 2022). Because many of these proteins possess distinct structural and functional features compared to their human homologs, they allow for selective toxicity, which is the cornerstone of antimicrobial therapy. However, the therapeutic utility of targeting these molecules is frequently challenged by the rapid emergence of antimicrobial resistance, where pathogens evolve mutations that reduce drug binding affinity or increase efflux (WHO, 2023). Consequently, this category remains a primary focus for the development of next-generation anti-infectives designed to overcome existing resistance mechanisms.

Other names

Microbial intracellular targetsPathogen-specific enzymesIntracellular antimicrobial targetsViral and bacterial intracellular proteins

Drugs targeting these entities typically act by inhibiting essential microbial processes, such as nucleic acid synthesis (e.g., fluoroquinolones inhibiting DNA gyrase), protein synthesis (e.g., macrolides binding to the 50S ribosome), or metabolic pathways (e.g., sulfonamides inhibiting folate synthesis) (NCBI, 2021; StatPearls, 2023).